Novo Nordisk A/S
NVONext catalyst
NNC0662-0419
Overweight
Get an email about NVO's next catalysts
Track Novo Nordisk A/S (NVO) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 19 more upcoming events in our data (NDA filing, Phase 2 readout, Phase 3 readout and more).See the timeline
20 upcoming, 1 past
NNC0662-0419 Phase 2 Est. Readout
Primary completion for NNC0662-0419 trial (NCT07184632) in Overweight
SourceNDA Filing - etavopivat
For sickle cell disease. Novo Nordisk's etavopivat demonstrated significant efficacy in late-stage sickle cell disease trials with a 27% reduction in vaso-occlusive crises and 48.7% hemoglobin response. The company plans to seek FDA approval in the second half of 2026.
UBT251 Phase 2 Est. Readout
Primary completion for UBT251 trial (NCT07395687) in Overweight
SourceInsulin icodec Phase 3 Est. Readout
Estimated primary completion for Insulin icodec trial (NCT07076199) in Diabetes Mellitus, Type 1. Topline data typically follows completion by weeks to months.
SourceZiltivekimab Phase 3 Est. Readout (ARTEMIS)
Estimated primary completion for Ziltivekimab trial (NCT06118281) in Cardiovascular Risk. Topline data typically follows completion by weeks to months.
SourceCagriSema (Cagrilintide B and Semaglutide I) Phase 3 Est. Readout
Estimated primary completion for CagriSema (Cagrilintide B and Semaglutide I) trial (NCT07011667) in Obesity. Topline data typically follows completion by weeks to months.
SourceOther - Wegovy
For weight management. Novo Nordisk announced significant reductions in US list prices for Wegovy, Ozempic, and Rybelsus (semaglutide medicines) effective January 1, 2027, as part of efforts to expand patient access.
Cagrilintide Phase 3 Est. Readout (RENEW 2)
Primary completion for Cagrilintide trial (NCT07220642) in Obesity
SourceHow NVO's past catalysts played out
Market Overview
Stock performance and key metrics
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S (wholly owned by the Novo Nordisk Foundation) which holds approximately 28.1% of its shares and a majority (77.1%) of its voting shares.
Websiteoral anti-diabetic drug
Diabetes
exenatide
Diabetes
repaglinide and metformin combination tablet
Diabetes
NNC0487-0111
Obesity
Insulin glargine U100
Diabetes Mellitus, Type 2
repaglinide
Diabetes
biphasic human insulin 50
Diabetes
insulin human
Diabetes
inhaled human insulin
Diabetes
Etavopivat
Sickle Cell Disease
CagriSema (Cagrilintide B and Semaglutide I)
Obesity
Canagliflozin
Diabetes
sulfonylurea
Diabetes
vatreptacog alfa (activated)
Congenital Bleeding Disorder
Efruxifermin
NASH - Nonalcoholic Steatohepatitis
biphasic insulin aspart 70
Diabetes
17-beta estradiol
Genetic Disorder
Saxenda
Obesity
estradiol
Menopause
Semagludtide
Early Alzheimer's Disease
Etavopivat Tablets High dose
Sickle Cell Disease
Insulin Fiasp
Type 2 Diabetes Treated With Insulin
Etavopivat Tablets
Sickle Cell Disease
glibenclamide
Diabetes
eptacog alfa (activated)
Acquired Bleeding Disorder
Cagrisema
Obesity
Etavopivat B
Sickle Cell Disease
Etavopivat C
Sickle Cell Disease
Norditropin
Growth Hormone Disorder
IDegLira
Diabetes Mellitus
Insulin infusion with a goal
Cardiac Surgical Procedures
Hemohes® (Hydroxyethyl starch)
Severe Sepsis
Etavopivat Tablets Low dose
Sickle Cell Disease
nexium
Type 2 Diabetes
Liraglutide Pen Injector
Pre Diabetes
Insulin Aspart, BIAsp 70, BIAsp50, Human Insulin
Diabetes Mellitus, Type 1
Insulin Asparte
Cystic Fibrosis
Zenagamtide
Type 2 Diabetes
estradiol/norethisterone acetate (NETA)
Menopause
biphasic human insulin 30
Diabetes
Estradiol Vaginal
Vulvovaginal Atrophy
Recombinant Activated Factor VII (rFVIIa)
Intracerebral Hemorrhage
insulin
Diabetes
Metformin XR plus liraglutide
Gestational Diabetes Mellitus
insulin glargine
Diabetes
Metformin on top of intensive insulin therapy
Type 2 Diabetes Mellitus
Recombinant Factor VIIa
Intracerebral Hemorrhage
SOMATROPINE* : Norditropine® simplexx®
Anorexia Nervosa
NovoLog
Type 2 Diabetes Treated With Insulin
Ziltivekimab C
Cardiovascular Risk
rosiglitazone and metformin combination tablet
Diabetes
biphasic insulin aspart
Diabetes
Cagrilintide
Obesity or Overweight
Concizumab
Congenital Bleeding Disorder
biphasic human insulin
Diabetes
Insulin Icodec
Diabetes Mellitus, Type 2
human insulin
Diabetes
insulin NPH
Diabetes
turoctocog alfa pegol
Congenital Bleeding Disorder
rosiglitazone
Diabetes
biphasic insulin aspart 50
Diabetes
DPP-4 inhibitor
Diabetes
NNC0365-3769 (Mim8)
Haemophilia A
Norditropin®
Growth Hormone Deficiency in Children
Ziltivekimab B
Cardiovascular Risk
NNC0365-3769 (Mim8) PPX
Haemophilia A
Faster aspart
Diabetes Mellitus, Type 1
basal insulin
Diabetes
Etavopivat A
Sickle Cell Disease
sulphonylurea
Diabetes
nonacog beta pegol
Congenital Bleeding Disorder
NPH insulin
Diabetes
Turoctocog alfa
Haemostasis
Insuline glargine U100 (reduced)
Diabetes Mellitus, Type 2
Ziltivekimab
Heart Failure
Oral semaglutide
Diabetes Mellitus, Type 2
Faster-acting insulin aspart
Diabetes
somapacitan
Adult Growth Hormone Deficiency
human soluble insulin
Diabetes
NNC6019-0001
Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Mim8
Haemophilia A
IcoSema
Type 2 Diabetes
insulin detemir
Diabetes
somatropin
Growth Hormone Disorder
biphasic insulin aspart 30
Diabetes
activated recombinant human factor VII
Acquired Bleeding Disorder
Semaglutide
Obesity
insulin aspart
Diabetes
insulin degludec/liraglutide
Diabetes
insulin degludec
Diabetes
catridecacog
Congenital Bleeding Disorder
liraglutide
Diabetes
insulin degludec/insulin aspart
Diabetes
insulin lispro
Diabetes
Semaglutide J
Diabetes Mellitus, Type 2
turoctocog alfa pegol (N8-GP)
Haemophilia A
DCR-PHXC
Primary Hyperoxaluria Type 1 (PH1)
CDR132L
Heart Failure
NNC0114-0006
Diabetes
NNC109-0012
Inflammation
NNC0194-0499
Alcohol-related Liver Disease
NNC0385-0434 A
Atherosclerotic Cardiovascular Disease
NNC0480-0389
Diabetes Mellitus, Type 2
COR-001
Anemia
Semaglutide (administered by PDS290 pen)
Healthy Volunteers Diabetes Mellitus, Type 2
autologous stored platelets
Bleeding
insulin 338 (GIPET I)
Diabetes
Cagrilintide + semaglutide
Alcohol-related Liver Disease
NNC0662-0419
Overweight
NNC126-0083
Growth Hormone Disorder
EX1000
Diabetes
orlistat
Metabolism and Nutrition Disorder
Eptacog alfa
Congenital Bleeding Disorder
NNC0519-0130
Diabetes Mellitus, Type 2
UBT251
Overweight
nedosiran
Primary Hyperoxaluria
activated recombinant human factor VII, long acting
Congenital Bleeding Disorder
NNC0174 0833
Non-alcoholic Steatohepatitis
NNC0194 0499
Non-alcoholic Steatohepatitis
Fast-acting insulin aspart
Diabetes Mellitus, Type 1
Semaglutide and NNC0165-1875
Obesity
Norditropin SimpleXx (growth hormone)
Growth Hormone Deficiency
NNC0090-2746
Diabetes
Regular Human Insulin
Type 2 Diabetes Mellitus
Semaglutide Pen Injector
NAFLD
recombinant interleukin-21
Cancer
NNC 0151-0000-0000
Inflammation
Firsocostat
Nonalcoholic Steatohepatitis
NDec - oral decitabine-tetrahydrouridine
Sickle Cell Disease
GlucoNorm
Type 2 Diabetes
Semaglutide (SEMA)
Nonalcoholic Steatohepatitis
Semaglutide (administered by DV3396 pen)
Healthy Volunteers Diabetes Mellitus, Type 2
Dasatinib
Osteopenia, Osteoporosis
caelyx (pegylated liposomal doxorubicin)
Cancer
Everolimus (Afinitor®)
Postmenopausal Women
somatotropin
Muscular Atrophy, Spinal
Norditropin® FlexPro® pen
Growth Hormone Disorder
intensive insulin therapy to maintain normoglycemia
Critical Illness
Cilofexor
Nonalcoholic Steatohepatitis
NNC0487-0111 subcutanous
Type 2 Diabetes (T2D)
Mixed Meal Tolerance Test with paracetamol
Type 1 Diabetes Mellitus
NNC0487-0111 oral
Type 2 Diabetes (T2D)
Actrapid HM
Diabetes, Type I
Growth Hormone
TBI (Traumatic Brain Injury)
Dipeptidyl peptidase-4 inhibitors
Diabetes Mellitus, Type 2
Dobutamine
Acute Myocardial Infarction
NNC0174-0833
Overweight
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
oral anti-diabetic drug | Phase 3 | Diabetes | - | - |
exenatide | Phase 3 | Diabetes | - | - |
repaglinide and metformin combination tablet | Phase 3 | Diabetes | - | - |
NNC0487-0111 | Phase 3 | Obesity | - | - |
Insulin glargine U100 | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
repaglinide | Phase 3 | Diabetes | - | - |
biphasic human insulin 50 | Phase 3 | Diabetes | - | - |
insulin human | Phase 3 | Diabetes | - | - |
inhaled human insulin | Phase 3 | Diabetes | - | - |
Etavopivat | Phase 3 | Sickle Cell Disease | - | - |
CagriSema (Cagrilintide B and Semaglutide I) | Phase 3 | Obesity | - | - |
Canagliflozin | Phase 3 | Diabetes | - | - |
sulfonylurea | Phase 3 | Diabetes | - | - |
vatreptacog alfa (activated) | Phase 3 | Congenital Bleeding Disorder | - | - |
Efruxifermin | Phase 3 | NASH - Nonalcoholic Steatohepatitis | - | - |
biphasic insulin aspart 70 | Phase 3 | Diabetes | - | - |
17-beta estradiol | Phase 3 | Genetic Disorder | - | - |
Saxenda | Phase 3 | Obesity | - | - |
estradiol | Phase 3 | Menopause | - | - |
Semagludtide | Phase 3 | Early Alzheimer's Disease | - | - |
Etavopivat Tablets High dose | Phase 3 | Sickle Cell Disease | - | - |
Insulin Fiasp | Phase 3 | Type 2 Diabetes Treated With Insulin | - | - |
Etavopivat Tablets | Phase 3 | Sickle Cell Disease | - | - |
glibenclamide | Phase 3 | Diabetes | - | - |
eptacog alfa (activated) | Phase 3 | Acquired Bleeding Disorder | - | - |
Cagrisema | Phase 3 | Obesity | - | - |
Etavopivat B | Phase 3 | Sickle Cell Disease | - | - |
Etavopivat C | Phase 3 | Sickle Cell Disease | - | - |
Norditropin | Phase 3 | Growth Hormone Disorder | - | - |
IDegLira | Phase 3 | Diabetes Mellitus | - | - |
Insulin infusion with a goal | Phase 3 | Cardiac Surgical Procedures | - | - |
Hemohes® (Hydroxyethyl starch) | Phase 3 | Severe Sepsis | - | - |
Etavopivat Tablets Low dose | Phase 3 | Sickle Cell Disease | - | - |
nexium | Phase 3 | Type 2 Diabetes | - | - |
Liraglutide Pen Injector | Phase 3 | Pre Diabetes | - | - |
Insulin Aspart, BIAsp 70, BIAsp50, Human Insulin | Phase 3 | Diabetes Mellitus, Type 1 | - | - |
Insulin Asparte | Phase 3 | Cystic Fibrosis | - | - |
Zenagamtide | Phase 3 | Type 2 Diabetes | - | - |
estradiol/norethisterone acetate (NETA) | Phase 3 | Menopause | - | - |
biphasic human insulin 30 | Phase 3 | Diabetes | - | - |
Estradiol Vaginal | Phase 3 | Vulvovaginal Atrophy | - | - |
Recombinant Activated Factor VII (rFVIIa) | Phase 3 | Intracerebral Hemorrhage | - | - |
insulin | Phase 3 | Diabetes | - | - |
Metformin XR plus liraglutide | Phase 3 | Gestational Diabetes Mellitus | - | - |
insulin glargine | Phase 3 | Diabetes | - | - |
Metformin on top of intensive insulin therapy | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Recombinant Factor VIIa | Phase 3 | Intracerebral Hemorrhage | - | - |
SOMATROPINE* : Norditropine® simplexx® | Phase 3 | Anorexia Nervosa | - | - |
NovoLog | Phase 3 | Type 2 Diabetes Treated With Insulin | - | - |
Ziltivekimab C | Phase 3 | Cardiovascular Risk | - | - |
rosiglitazone and metformin combination tablet | Phase 3 | Diabetes | - | - |
biphasic insulin aspart | Phase 3 | Diabetes | - | - |
Cagrilintide | Phase 3 | Obesity or Overweight | - | - |
Concizumab | Phase 3 | Congenital Bleeding Disorder | - | - |
biphasic human insulin | Phase 3 | Diabetes | - | - |
Insulin Icodec | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
human insulin | Phase 3 | Diabetes | - | - |
insulin NPH | Phase 3 | Diabetes | - | - |
turoctocog alfa pegol | Phase 3 | Congenital Bleeding Disorder | - | - |
rosiglitazone | Phase 3 | Diabetes | - | - |
biphasic insulin aspart 50 | Phase 3 | Diabetes | - | - |
DPP-4 inhibitor | Phase 3 | Diabetes | - | - |
NNC0365-3769 (Mim8) | Phase 3 | Haemophilia A | - | - |
Norditropin® | Phase 3 | Growth Hormone Deficiency in Children | - | - |
Ziltivekimab B | Phase 3 | Cardiovascular Risk | - | - |
NNC0365-3769 (Mim8) PPX | Phase 3 | Haemophilia A | - | - |
Faster aspart | Phase 3 | Diabetes Mellitus, Type 1 | - | - |
basal insulin | Phase 3 | Diabetes | - | - |
Etavopivat A | Phase 3 | Sickle Cell Disease | - | - |
sulphonylurea | Phase 3 | Diabetes | - | - |
nonacog beta pegol | Phase 3 | Congenital Bleeding Disorder | - | - |
NPH insulin | Phase 3 | Diabetes | - | - |
Turoctocog alfa | Phase 3 | Haemostasis | - | - |
Insuline glargine U100 (reduced) | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
Ziltivekimab | Phase 3 | Heart Failure | - | - |
Oral semaglutide | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
Faster-acting insulin aspart | Phase 3 | Diabetes | - | - |
somapacitan | Phase 3 | Adult Growth Hormone Deficiency | - | - |
human soluble insulin | Phase 3 | Diabetes | - | - |
NNC6019-0001 | Phase 3 | Transthyretin Amyloid Cardiomyopathy (ATTR CM) | - | - |
Mim8 | Phase 3 | Haemophilia A | - | - |
IcoSema | Phase 3 | Type 2 Diabetes | - | - |
insulin detemir | Phase 3 | Diabetes | - | - |
somatropin | Phase 3 | Growth Hormone Disorder | - | - |
biphasic insulin aspart 30 | Phase 3 | Diabetes | - | - |
activated recombinant human factor VII | Phase 3 | Acquired Bleeding Disorder | - | - |
Semaglutide | Phase 3 | Obesity | - | - |
insulin aspart | Phase 3 | Diabetes | - | - |
insulin degludec/liraglutide | Phase 3 | Diabetes | - | - |
insulin degludec | Phase 3 | Diabetes | - | - |
catridecacog | Phase 3 | Congenital Bleeding Disorder | - | - |
liraglutide | Phase 3 | Diabetes | - | - |
insulin degludec/insulin aspart | Phase 3 | Diabetes | - | - |
insulin lispro | Phase 3 | Diabetes | - | - |
Semaglutide J | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
turoctocog alfa pegol (N8-GP) | Phase 3 | Haemophilia A | - | - |
DCR-PHXC | Phase 3 | Primary Hyperoxaluria Type 1 (PH1) | - | - |
CDR132L | Phase 2 | Heart Failure | - | - |
NNC0114-0006 | Phase 2 | Diabetes | - | - |
NNC109-0012 | Phase 2 | Inflammation | - | - |
NNC0194-0499 | Phase 2 | Alcohol-related Liver Disease | - | - |
NNC0385-0434 A | Phase 2 | Atherosclerotic Cardiovascular Disease | - | - |
NNC0480-0389 | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
COR-001 | Phase 2 | Anemia | - | - |
Semaglutide (administered by PDS290 pen) | Phase 2 | Healthy Volunteers Diabetes Mellitus, Type 2 | - | - |
autologous stored platelets | Phase 2 | Bleeding | - | - |
insulin 338 (GIPET I) | Phase 2 | Diabetes | - | - |
Cagrilintide + semaglutide | Phase 2 | Alcohol-related Liver Disease | - | - |
NNC0662-0419 | Phase 2 | Overweight | - | - |
NNC126-0083 | Phase 2 | Growth Hormone Disorder | - | - |
EX1000 | Phase 2 | Diabetes | - | - |
orlistat | Phase 2 | Metabolism and Nutrition Disorder | - | - |
Eptacog alfa | Phase 2 | Congenital Bleeding Disorder | - | - |
NNC0519-0130 | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
UBT251 | Phase 2 | Overweight | - | - |
nedosiran | Phase 2 | Primary Hyperoxaluria | - | - |
activated recombinant human factor VII, long acting | Phase 2 | Congenital Bleeding Disorder | - | - |
NNC0174 0833 | Phase 2 | Non-alcoholic Steatohepatitis | - | - |
NNC0194 0499 | Phase 2 | Non-alcoholic Steatohepatitis | - | - |
Fast-acting insulin aspart | Phase 2 | Diabetes Mellitus, Type 1 | - | - |
Semaglutide and NNC0165-1875 | Phase 2 | Obesity | - | - |
Norditropin SimpleXx (growth hormone) | Phase 2 | Growth Hormone Deficiency | - | - |
NNC0090-2746 | Phase 2 | Diabetes | - | - |
Regular Human Insulin | Phase 2 | Type 2 Diabetes Mellitus | - | - |
Semaglutide Pen Injector | Phase 2 | NAFLD | - | - |
recombinant interleukin-21 | Phase 2 | Cancer | - | - |
NNC 0151-0000-0000 | Phase 2 | Inflammation | - | - |
Firsocostat | Phase 2 | Nonalcoholic Steatohepatitis | - | - |
NDec - oral decitabine-tetrahydrouridine | Phase 2 | Sickle Cell Disease | - | - |
GlucoNorm | Phase 2 | Type 2 Diabetes | - | - |
Semaglutide (SEMA) | Phase 2 | Nonalcoholic Steatohepatitis | - | - |
Semaglutide (administered by DV3396 pen) | Phase 2 | Healthy Volunteers Diabetes Mellitus, Type 2 | - | - |
Dasatinib | Phase 2 | Osteopenia, Osteoporosis | - | - |
caelyx (pegylated liposomal doxorubicin) | Phase 2 | Cancer | - | - |
Everolimus (Afinitor®) | Phase 2 | Postmenopausal Women | - | - |
somatotropin | Phase 2 | Muscular Atrophy, Spinal | - | - |
Norditropin® FlexPro® pen | Phase 2 | Growth Hormone Disorder | - | - |
intensive insulin therapy to maintain normoglycemia | Phase 2 | Critical Illness | - | - |
Cilofexor | Phase 2 | Nonalcoholic Steatohepatitis | - | - |
NNC0487-0111 subcutanous | Phase 2 | Type 2 Diabetes (T2D) | - | - |
Mixed Meal Tolerance Test with paracetamol | Phase 2 | Type 1 Diabetes Mellitus | - | - |
NNC0487-0111 oral | Phase 2 | Type 2 Diabetes (T2D) | - | - |
Actrapid HM | Phase 2 | Diabetes, Type I | - | - |
Growth Hormone | Phase 2 | TBI (Traumatic Brain Injury) | - | - |
Dipeptidyl peptidase-4 inhibitors | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
Dobutamine | Phase 2 | Acute Myocardial Infarction | - | - |
NNC0174-0833 | Phase 2 | Overweight | - | - |
diabetes
9 drugs in this indication
obesity
2 drugs in this indication
Diabetes Mellitus, Type 2
2 drugs in this indication
Congenital Bleeding Disorder
2 drugs in this indication
Haemophilia A
2 drugs in this indication
weight management
2 drugs in this indication
CKD
1 drug in this indication
gastric issues
1 drug in this indication
MACE risk reduction
1 drug in this indication
hemophilia A
1 drug in this indication
Obesity or Overweight
1 drug in this indication
Heart Failure
1 drug in this indication
Inflammation
1 drug in this indication
Transthyretin Amyloid Cardiomyopathy (ATTR CM)
1 drug in this indication
obesity, overweight
1 drug in this indication
Overweight
1 drug in this indication
weight reduction
1 drug in this indication
idiopathic short stature in children
1 drug in this indication
obesity with excess liver fat
1 drug in this indication
haemophilia A, with or without inhibitors in adults and children
1 drug in this indication
obesity-related heart failure with preserved ejection fraction (HF-pEF) and type 2 diabetes
1 drug in this indication
weight loss
1 drug in this indication
Healthy Volunteers Diabetes Mellitus, Type 2
1 drug in this indication
Growth Hormone Deficiency in Children
1 drug in this indication
Type 2 diabetes in children 10 years of age and older
1 drug in this indication
MASH (metabolic dysfunction-associated steatohepatitis)
1 drug in this indication
obesity/weight management
1 drug in this indication
sickle cell disease
1 drug in this indication
weight loss/chronic weight management
1 drug in this indication
sickle cell disease (adolescents and adults)
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Novo Nordisk A/S's drug pipeline?→
CatalystAlert tracks 147 drug candidates in Novo Nordisk A/S's (NVO) pipeline across Phase 3, Phase 2. Its lead program is Etavopivat (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Novo Nordisk A/S's next FDA catalyst?→
Novo Nordisk A/S's (NVO) next tracked catalyst is a Phase 2 readout expected December 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track NVO biotech catalysts?→
Add NVO to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Novo Nordisk A/S's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.
